Advertisement
Am J Health-Syst Pharm
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hermsen, E.
Right arrow Articles by McNabb, J
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hermsen, E.
Right arrow Articles by McNabb, J
American Journal of Health-System Pharmacy, Vol 61, Issue 3, 245-256
Copyright © 2004 by American Society of Health-System Pharmacists


Articles

Discontinuation of prophylaxis for HIV-associated opportunistic infections in the era of highly active antiretroviral therapy

ED Hermsen, HE Wynn, and J McNabb


PURPOSE: The rationale for recent changes in guidelines for the prevention of opportunistic infections (OIs) in HIV-infected persons is discussed. SUMMARY: The epidemiology of AIDS has changed significantly since the advent of highly active antiretroviral therapy (HAART). Furthermore, the impact of HIV-associated OIs has decreased, leading to changes in the guidelines and recommendations for primary and secondary prophylaxis for such infections. While many patients can now be considered for discontinuation of suppressive therapy, clinical decision making surrounding the discontinuation of primary or secondary prophylaxis must take into account each patient's individual circumstances. Continued surveillance and careful monitoring of patients who stop prophylaxis will be critical to the overall success of OI treatment and prevention programs. CONCLUSION: The decision to discontinue primary or secondary prophylaxis for HIV associated OIs should be made on a case-by-case basis.
 



This article has been cited by other articles:


Home page
Journal of Pharmacy PracticeHome page
C. W. James and S. Szabo
Introduction: HIV-Related Opportunistic Infections in the 21st Century
Journal of Pharmacy Practice, February 1, 2006; 19(1): 3 - 4.
[PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Society of Health-System Pharmacists.
Advertisement